Durvalumab improved invasive disease-free survival, distant disease-free survival, and overall survival.
Data showed increases in endometrial cancer and obesity in women younger than 40.
Nearly three-quarters of patients responded to treatment.
The signature was prognostic for locoregional recurrence.
Rates of SARS-CoV-2 infection and COVID-19-related death were similar among patients receiving cytotoxic and non-cytotoxic therapy.
Endocrine therapy was associated with fewer adverse events.
Younger patients had a significant decrease in sleep time on days they received dexamethasone.
Black patients were more likely than White patients to have distant metastases.
The median PFS was 8.5 months in the pasireotide arm, 12.5 months in the everolimus arm, and 16.5 months in the combination arm.
The cumulative incidence of bone fractures was below 5% in BPA recipients.
Pembrolizumab improved progression-free survival but not overall survival.
The size of cancer-associated macrophage-like cells was linked to progression-free survival as well.
In patients with melanoma and confirmed progression on a PD-1, lenvatinib plus pembrolizumab demonstrated clinically meaningful responses.
The 1-year overall survival rate was 71%.
Improvements were seen in event-free and overall survival.
The combination improved invasive disease-free survival and distant relapse-free survival.
Abiraterone prolonged radiographic progression-free survival by 2.5 years.
There was no improvement in overall survival.
Rates of relapse-free and overall survival were high as well, exceeding 90%.
Overall and progression-free survival were similar between the treatment arms.